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Review of meeting: Antibiotic discovery: Exploiting new 
understanding of mechanism of action 
Clinical needs for new antibacterial agents derive from 
the dissemination of bacterial resistance and the 
emergence of opportunistic pathogens, especially in the 
growing population of those with debilitated immune 
systems. One approach to ensure the future availability 
of effective drugs is to increase the number of 
innovative molecules. 
‘Antibiotic Discovery,’ a conference organized by 
International Business Communications, coniprised 17 
oral presentations and five posters covering current and 
future research on new antibacterial agents. The 
following topics were discussed: 
Unexploited antibacterial targets (biosynthetic 
pathways, bacterial enzymes) and gene-based 
strategies. 
Molecular combinatorial libraries and high- 
throughput screening. 
New methodologies to evaluatt. the efficacy of 
new antibacterial agents. 
Peptide and protein antimicrobial agents. 
Unexploited antibacterial targets 
John E Barrett (R.W. Johnson Pharmaceutical 
Research Institute, Raraitan, NJ, USA) asked the 
question, ‘Is inhibition o f  bacterial virulence a satis- 
factory goal in antibacterial therapy?’ Bacterial 
virulence involves several processes, such as adhesion, 
tissue colonization, invasion, and evasion of host 
iimnune responses, as well as the production of specific 
factors (surface structures, enzymes, toxins, etc.). Also 
involved in virulence is the capacity of microorganisms 
to receive, and respond to, environmental stimuli. Two- 
component signaling systems active in these processes 
have been identified in a number of ba’cteria. In fact, it 
is unlikely that a pathogen could survive the varied and 
changing environment of the humarr body without 
having at least one such two-component system. Such 
systems consist of a sensor protein, which, under 
particular conditions, becomes autophosphorylated. In 
this state, the sensor protein can act as a phospho- 
transferase and phosphorylate a regulatory protein (the 
transducer), which then can control the transcription 
of specific genes. 
A number of virulence genes are under the control 
of two-component systems. An intere:jting example is 
that of the genes involved in exopolysaccharide 
production by Pseudomonas aeruginora. The expression 
of the alginate genes in this species is regulated by 
several proteins, including those of the two-component 
system. Two of these rtgulatory proteins are AlgR1, the 
DNA-binding respons,e regulator that transcriptionally 
activates alginate gene expression, and AlgR2, the 
kinase that modifies AlgRl via phosphorylation, 
thereby enhancing its activity. In a screen for alb. rinate- 
suppressing agents (which were not necessarily 
antibacterial agents), as originally reported by Eli Lilly 
Laboratories, several compounds were identified as 
potent inhibitors of alginate gene expression. These 
inhibited the phosphorylation/dephosphorylation of 
AlgR2 and the DNA--binding activity of AlgKl . 
Other two-component systems have been des- 
cribed that control chemotaxis, osnioregulation, 
sporulation, responses to nitrogen, phosphate or carbon 
source availability, host-pathogen interactions, arid 
reactions to many other environmental stimuli. 
Joyce A. Sutclifle (Pfizer, Groton, CT, USA) 
presented an overview of unexploited antibacterial 
targets in macromole<:ular biosynthetic pathways. She 
focused her talk on DNA replication, which in bacteria 
is a highly regulated process coordinated with other 
processes required for cell growth and division. The 
DNA replicative machinery of bacteria constitutes an 
attractive, largely unexplored set of targets for the 
development o f  new iintibiotics. In Escherichia coli, for 
example, over 30 proteins are required to replicate 
DNA, including the DNA polymerase I11 holoenzyme. 
The most convenient way to monitor DNA replication 
is by measuring the incorporation of acid-soluble 
deoxynucleoside triphosphates into acid-insoluble 
DNA. It is also possible to monitor the uptake and 
incorporation of a radiolabeled precursor into 
permeabilized Gram-negative or Grain-positive cells. 
Another strategy prclposed is that of screening for 
inhibitors by using genetically engineered bacterial 
strains that either contain temperature-conditional 
mutations in the gene1:s) of interest or overproduce one 
or several proteins involved in DNA synthesis. 
Certain molecules have been described as in- 
hibitors of DNA synthesis: 
0 DNA initiatioqi inhibitor 
DNAC (3-decynoyl-N-acetylcysteaniine) 
interferes w‘ith b-hydroxydecanoyl thioester 
dehydrase, preventing activation of DnaA 
0 DNA primingr’elongation inhibitors 
anti-b IgG blocks formation of DNA poly- 
merase I11 holoenzyme 
6-(arylaminp) and 6-(arylazo) pyrimidines 
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inducing formation of ternary complexes of 
DNA polymerase 111 
2'-deoxj-2'-azido CTP, ATP, GTP, UTP, 
inhibit DnaG primase of E. coli 
0 General inhibitors 
2'(3') trinitrophenyl ATP blocks initiation 
complex formation, ATP binding by 
holoenzyme, and DNA-dependent ATPase 
activity of holoenzyme 
0 DNA gyrase/topoisomerase IV inhibitors 
quinolones 
coumarins 
other reported structures (flavones, clero- 
cidin, cyclothialidin). 
Karen Bush (Lederle Laboratories, Pearl River, 
NY, USA) discussed p-Lactamase inhibitors. p- 
Lactamases are largely responsible for bacterial resis- 
tance to p-lactam antibiotics, and the development of 
new p-lactams is closely linked to the emergence of 
enzymes with altered specificities and expression. p- 
Lactamases have been traditionally classified on the basis 
of molecular weight, substrate profile, inhibitor profile, 
isoelectric point, or a combination of these four para- 
meters. As their amino acid sequence and mechanism 
of catalysis have become known, they have been classed 
according to the ABCD classification scheme. In- 
hibitors of class B and C enzymes are being explored. 
Class B enzymes are chromosomally encoded, zinc 
metalloenzymes, possessing a thiol group which acts as 
a ligand to bind zinc. Their activity spectrum includes 
carbapenems and cephamycins, both of which are 
generally regarded as P-lactamase stable. There are no 
known inhibitors of the class B p-lactamases other than 
metal chelators. 
Recently, two natural products that inhibit 
metalloenzymes have been reported, LL-lOG568a and 
LL-lOG568p. Their activities against two p-lactamases 
are indicated in Table 1. 
The search for other compounds having this 
activity will undoubtedly be aided by the acquisition of 
extensive knowledge of the zinc proteases. Under- 
standing the mechanism of action of the zinc p- 
lactamases is also important. 
Class C enzymes are chromosonially encoded p- 
lactamases, either constitutive or inducible. They are 
typically cephalosporinases and are found in Gram- 
negative bacteria. Inhibitors of class C @-lactamases are 
another promising area of research. 
John Clardy (Cornell University, Ithaca, NY, USA) 
discussed another enzyme, chorismate mutase, that may 
represent a new target. Chorismate mutase catalyzes the 
rearrangement of chorismic acid to prephenetic acid, 
which is the first committed step in the biosynthesis of 
the aromatic amino acids. Recent structural studies on 
several naturally occurring chorismate mutases and on 
an antibody that catalyzes the same reaction have 
provided some insight into the catalytic mechanisms 
used by these proteins. The aromatic biosynthetic 
pathway is absent in mammals. At present, there is 
sufficient knowledge about the enzymes of the 
aromatic biosynthetic pathway and the reactions they 
catalyze on which to base the design of inhibitors 
(rational drug design). 
Recently, certain shikimic acid analogs were 
proposed as potential inhibitors of bacterial aromatic 
biosynthesis. For example, (6S)-6-fluoroshikimic acid 
inhibits the growth of E.  coli and protects mice 
challenged intraperitoneally with the same bacteria. 
Molecular combinatorial libraries and high-throughput 
screening 
Four presentations dealt with combinatorial chemistry. 
Unlike traditional synthetic chemistry, which focuses 
on making a single compound at a time, combinatorial 
chemistry involves the repetitive connection of a 
variety of structural building blocks to yield a wide 
array of compounds. In the space of just a few years, 
virtually every pharmaceutical company has introduced 
core groups, the basic structural units from which 
combinatorial compounds are built. 
D. J. Ecker (Isis Pharmaceuticals, Carlsbad, CA, 
USA) reviewed a broad variety of new synthesis and 
screening methods, currently grouped under the rubric 
'combinatorial.' These methods include: (1) parallel 
chemical synthesis and testing of multiple individual 
compounds or compound mixtures in solution; (2) 
synthesis and testing of compounds on solid supports; 
and (3) biochemical or organism-based synthesis of 
Table 1 
P-Lactamase-producing Clavulanate LL-lOG568a LL-lOC568p 
organism Enzyme ICjo (pM) ICso (pM) IC50 (ClM) 
Bacteroides j q i l i s  CrrA > 1000 0.29 0.14 
Xanthornonas maltophilia L1 >loo 1.2 0.60 
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d’f L-amino acids are susceptible to 
and are rarely active when 
so that applicability is limited to 
use. Antimicrobial peptides 
and/or unnatural amino acids are 
stable toward proteolysis. A series 
a high level of activity against 
was presented. The interest of 
and peptidoniiinetic conibinatorial 
Inc., Bothell, WA, USA), who 
presentation on this topic, emphasized 
continue to offer a source of 
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(School of Pharmacy, University of 
USA) focused her presentation on 
des, which she has shown to be 
structure and original with regard to 
qction. 
disc.ussed. 
biological oligomers coupled to selection and anipli- 
fication strategies. 
Corribinatorial drug motifs are difficult to classi@. 
The basic structure of the synthesized niolecules is either 
monomeric or oligomeric. In the strategy termed 
‘monomeric decoration,’ which follows the example of 
classical niedicinal chemistry a basic scaffold with 
multiple sites for substitution is ‘decorated’ with a 
variety of diverse functionalities. Placing the diverse 
functionalities in different positions relative to each other 
on the scaffold creates new compounds. A number of 
modified simple sugars can be constructed in this way 
In nature, molecular diversity is achieved by the 
oligonierization of a small number of niononiers in a 
large number of ways (e.g. DNA fkom nucleotides; 
proteins from amino acids). A selection is iniposed so 
that the most ‘fit’ molecules ‘survive’ a challenge (e.g. 
binding to a desired target) that results in their 
ainplification . 
While biological oligoniers theniselves often have 
limited value as drugs (problems of stability, phar- 
niacokinetics, etc.), several strategies (can be employed 
to overcome the drawbacks of the natural biological 
oligoiners after they have been selected. Mimicking 
biologically interesting peptide structures with phar- 
maceutically acceptable molecules hai been a strategy 
purcued by niany groups over the past 20 years. The 
first generation of chemical oligoiners was derived from 
variations on the techniques for the cliemical synthesis 
of biological oligomers. Peptide analogs oligonierized 
through aniide linkage, which in this respect mimic 
natural peptides, are the most frequently encountered 
synthetic oligoiners. 
One of the mijor innovations of conibinatorial 
technology is the strategic linking of screening to 
synthcsic. The pharrilaceutical industry has developed a 
vast capacity to screen compounds in functional assays. 
However, to begin to tap the true power of coni- 
binatorial methods, mixtures of compounds, rather 
th:in single compounds, must be screened. Screening 
iiiistures hare a number of complications and caveats, 
a n d  at  present it is far from clear which strategy is best. 
For esaniple, there is always the chance that an active 
conipound will be overlooked because of an interfering 
compound in the same mixture. There niay also be 
present in a mixture niultiple active compounds, which 
must then be differentiated. It  is far koin certain that 
conibiizatorial methods will yield Iconipounds that 
represent major therapeutic advances. 
K.A. Houghten (Torrey Pines Institute for 
Molecular Studies and Houghten Pharmaceutical, Inc., 
San IXego, CA, USA) presented active antimicrobial 
peptides that have recently been identified by screening 
libraries, consisting of soluble synthetic peptides made 
I n  recent years, 
to study the activity 
(sub-MICs) on 
bioniaterial, and 
virulence factors. 
caused by antibiotics, 
between bacteria anc 
antibiotics on slow- 
A I U Y ~ U S  adhering to 
bioniaterial, such as 
developed in which 
several models have been proposed 
)f antibiotics at low concentrations 
bacterial structure, adherence to 
adierence to host cells and other 
Structural alterations in bacteria, 
lead to changes in the interaction 
host cells. To study the activity of 
growing or sessile Stapliylococrus 
in inert support (which mimics 
prostheses), a technique has been 
microporous membranes are 
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coated with fibronectin. Another in vitro method used 
involves evaluating how antibiotics interact with 
bacteria embedded in platelet-fibrin matrices that 
mimic cardiac vegetations. To study the interplay of 
antibiotics, bacteria and phagocytes, antibiotic uptake 
and release by phagocytes are measured, intracellular 
distribution and metabolism are monitored, and the 
capacity of the antibiotic to kill bacteria intracellularly 
is evaluated. Finally, there are monoparametric mouse 
models of bacteremia now available to evaluate the 
bactericidal activity of new drugs in vivo. 
C. K. Stover (PathoGenesis Corporation, Seattle, 
WA, USA) described the use of luciferase in vivo 
expression (LIVE) technology for in vivo efficacy 
studies of pathogenic mycobacteria. To facilitate the in 
vivo evaluation of compounds targeting Mycobactevium 
tuberculosis and other pathogenic mycobacteria, this 
group has developed infectious recombinant reporter 
strains that express luciferase at  levels high enough to 
be measured directly in infected tissue. With LIVE 
technology, it is possible to rapidly evaluate pathogen 
growth and antimicrobial inhibition in vivo. This 
system could also facilitate in vivo efficacy studies for 
other aspects of drug discovery. 
Peptide and protein antimicrobial agents 
M.H. West (Micrologix Biotech, Inc., Vancouver, 
Canada) introduced this topic by explaining that small 
cationic peptides are produced in nature as a major 
mechanism of defense against bacteria, fungi and 
viruses. To date, approximately 141 peptide structures 
have been isolated from various life-forms, ranging from 
bacteria to humans. This company has developed a 
DNA recombinant procedure for producing small 
cationic peptides, which would under usual conditions 
be lethal to the host bacterium, in bacterial strains 
engineered to resist the lethal effects. Multiple 
sequences that represent all known structural classes of 
antimicrobial peptides are expressed and purified. 
Among the peptides that have been selected is MBI 28, 
a cationic peptide with a-helical structure. This peptide 
binds to lipopolysaccharide (LPS), is active against 
Pseudomonas aeruginosa, and prevents the induction of 
the TNF response to endotoxin in cell lines and mice. 
I? Blackburn (Applied Microbiology, Inc., Tarry- 
town, NY, USA) presented a novel class of peptide 
antimicrobials: the lanthocins, which are a subclass of 
the bacteriocins. There are three types of lanthocins: 
type A (nisin, subtilin, epidermin), type B (cinnamicin, 
duramycin, ancovenin), and type C (actagardine, 
mersacidin). Nisin, an interesting example, is a 34 
amino acid cationic amphiphilic peptide that interacts 
with the bacterial plasma membrane. Nisin is bacteri- 
cidal for a broad range of antibiotic-resistant Gram- 
positive bacteria (staphylococci, streptococci) and acts 
on Gram-negative bacteria in the presence of a chelator 
via depolarization of the bacterial plasma membrane. 
Efficacious in mouse models of infection, nisin has no 
effect on mammalian cells and is a poor antigen. Nisin 
is currently used as an antibiotic in foods. Applied 
Microbiology, Inc. is developing nisin derivatives for 
the treatment of peptic ulcer disease, systemic 
nosocomial infections, skin infections, periodontal 
disease, and bovine mastitis. 
O.M. Conneely (Angennic, Inc., Houston, TX,  
USA) reported work done on lactoferrin, a multi- 
functional iron-binding glycoprotein that is a 
prominent component of human breast milk and is also 
found in other exocrine secretions, as well as in 
neutrophil granulocytes. Lactoferrin has potent, broad- 
spectrum antibacterial activity, because it can: 
0 sequester free iron, making it unavailable to 
support bacterial growth; 
0 kill bacteria by disrupting the LPS layer in the 
cell wall; 
0 regulate the immune response through the 
modulation of cytokine release by specific 
immune cells. 
The commercial exploitation of lactoferrin was not 
feasible until recombinant processes were developed for 
its production. In the recent past, limited quantities of 
biologically active recombinant human lactoferrin have 
been produced by the filamentous fungus Aspeyillus 
oryzae. At present, the protein is expressed in AspeTillus 
awamovi as a glucoamylase fusion polypeptide which is 
secreted into the growth medium and processed to 
mature human lactoferrin by exogenous KEX-2 
peptidase. The recombinant protein retains full 
biological activity in terms of its ability to bind iron and 
human enterocyte receptors, and functions as a potent, 
broad-spectrum antimicrobial agent. In the future, this 
protein could be used for the prophylaxis of septic 
shock or to increase the efficacy of antibiotics. 
Another interesting protein was presented by I? J. 
Scannon (XOMA Corporation, Berkeley, CA, USA). 
The bactericidal permeability-increasing (BPI) protein 
is a naturally occurring 55-kDa protein found in 
azurophilic granules of human neutrophils. BPI kills 
Gram-negative bacteria and neutralizes bacterial LPS. 
It is a ‘platform’ for the construction of multiple classes 
of anti-infective agents, as shown in Figure 1. 
NeuprexTM, a part of BPI, displays bactericidal 
activity against Gram-negative bacteria, binds to and 
neutralizes LPS (including endotoxin), and enhances 
antibiotic activity, in vitro and in mouse models, against 
Gram-negative bacteria, including antibiotic-resistant 
organisms. XMP peptides present in vitro fungicidal, 
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Figure 1 Natural bactericidal permeability-increasing protein (BPI) 
bactericidal (Gram-positive and Gram-negative) and 
endotoxin-neutralizing activities. 
New macrolides 
New inacrolide antibiotics for clinical and veterinary 
medicine were presented by H.A. Kirst (Eli Lilly 
Research Laboratories, Greenfield, I", USA). New 
antibiotics for veterinary medicine have been prepared 
from the 16-membered macrolide tylosin. Tilmicosin, 
for example, is used to treat bovine respiratory disease 
in cattle, and AIV-tylosiii is used for poultry and 
pigs. Antibiotics derived from either 14- or 16- 
membered niacrolides that have been introduced into 
human nicdicine include azithroniyciri, clarithroinycin, 
dirithroniycin, roxithroniycin, miokarnycin and rokita- 
niycin. A significant part of the 'macrolide renaissance' 
can be attributed to these new sernisynthetic anti- 
biotics, which have a larger antimicrobial spectrum 
than the older compounds, the m n e  intracellular 
penetration, and iniproved oral bioavailability and 
pharmacokinetics. More recently, research efforts have 
been directed toward further extending the advan- 
tagcous features of the inacrolide class. 
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